News

Opinion & Events,Research & Development,Therapeutic Areas
Halving fertility treatment costs could more than double ART births, study finds
read more
Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas
ReproNovo doses first participant in Phase 2 embryo implantation trial
read more
Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas
Novartis agrees $1.5bn Myricx Bio acquisition to strengthen ADC pipeline
read more
Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development
First patients dosed in Phase 1 trial of DLL3-targeted radiopharmaceutical for small cell lung cancer
read more
Central Nervous System,Drug Discovery & Development,Research & Development
CONNECTA highlights Fragile X data as Phase 2a trial advances
read more
Clinical & Regulatory,Medical devices,Research & Development
Xeltis passes halfway mark in US trial of haemodialysis vascular access device
read more
Medical devices,Therapeutic Areas
Active Care Group to develop specialist rehabilitation hospital in Stoke Mandeville
read more
Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development
Abivax reports positive Phase 3 maintenance data for obefazimod in ulcerative colitis
read more
Advanced Therapies,Biotech & Pharma Business,Drug Delivery & Formulation
Vect-Horus and Servier partner on targeted oligonucleotide therapies for rare CNS diseases
read more
Digital & Data,Research & Development,Therapeutic Areas
Fleming Initiative selects AWS to support global antimicrobial resistance platform
read more
Digital & Data,Research & Development,Therapeutic Areas
Study supports home-based EEG platform for Alzheimer’s clinical trials
read more
Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development
Lonza acquires Nona blood-brain barrier technology for CNS therapies
read more
Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development
FDA backs Telix Phase 3 ProstACT trial expansion into US
read more
Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics
Hansa completes €115M Idefirix licensing deal with SERB
read more
Clinical & Regulatory,Digital & Data,Pharmaceuticals and therapeutics,Research & Development
Remepy study links Hybridopa brain changes to improved Parkinson’s outcomes
read more
Digital & Data,Drug Discovery & Development,Research & Development
Basecamp integrates AI antibiotic and vaccine design models into Claude Science
read more

Halving fertility treatment costs could more than double ART births, study finds

ReproNovo doses first participant in Phase 2 embryo implantation trial

Novartis agrees $1.5bn Myricx Bio acquisition to strengthen ADC pipeline

First patients dosed in Phase 1 trial of DLL3-targeted radiopharmaceutical for small cell lung cancer

CONNECTA highlights Fragile X data as Phase 2a trial advances

Xeltis passes halfway mark in US trial of haemodialysis vascular access device

Active Care Group to develop specialist rehabilitation hospital in Stoke Mandeville

Abivax reports positive Phase 3 maintenance data for obefazimod in ulcerative colitis

Vect-Horus and Servier partner on targeted oligonucleotide therapies for rare CNS diseases

Fleming Initiative selects AWS to support global antimicrobial resistance platform

Study supports home-based EEG platform for Alzheimer’s clinical trials

Lonza acquires Nona blood-brain barrier technology for CNS therapies

FDA backs Telix Phase 3 ProstACT trial expansion into US

Hansa completes €115M Idefirix licensing deal with SERB

Remepy study links Hybridopa brain changes to improved Parkinson’s outcomes

Basecamp integrates AI antibiotic and vaccine design models into Claude Science

main menu

recent posts

Vandria reports Phase 1 data supporting Alzheimer’s development for VNA-318

Poolbeg Pharma doses first patient in POLB 001 trial to prevent cytokine release syndrome

Organic semiconductor breakthrough could improve wearable healthcare sensors

get connected